secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001104659-22-116252
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma Q3 2022: Record revenue $83.8M (+61% YoY); GAAP loss $(9.0M); adj. EPS $0.64; Cortrophin $12.6M
--------------------------------------------------------------------------------

- Record net revenues of $83.8M, up 61% YoY from $52.1M.
- GAAP net loss $(9.0M) and diluted loss per share $(0.55), compared to loss $(4.4M) and $(0.37) in Q3 2021.
- Adjusted non-GAAP EBITDA $19.6M (nearly double Q2 2022) and adjusted diluted EPS $0.64, down from $1.01 in Q3 2021.
- Cortrophin net sales $12.6M; cumulative patient cases 765+; reiterated full-year Cortrophin revenue guidance $40-45M; full-company guidance also reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000110465922116252/0001104659-22-116252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000110465922116252/tm2230118d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer